Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSelectHealth Compounded Medications Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedSelectHealthPolicy 325

    Compounded Medications

    Customize your policy alerts

    Sign up for SelectHealth Policy 325 alerts

    Get alerted when Policy 325 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage criteria for compounded medications across SelectHealth Commercial, Medicare (CMS), and Community Care (Medicaid); specifies when compounded prescriptions are medically necessary and includes billing/coding and prior authorization guidance.

    Policy Summary
    PayerSelectHealth
    PolicyCompounded Medications
    Policy CodePolicy 325
    Change TypeMaterial revisions and multiple prior updates (additions and clarifications)
    Effective DateDec 21, 2023
    Last ReviewFeb 3, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and provide clinical documentation showing the compound contains at least one FDA‑approved legend drug in therapeutic amounts and justification if similar to a commercial product.
    SourceLink
    POLICY UPDATE CHANGES

    For Commercial Plan Policy, added four diagnostic tests to list of exclusions: RNAse L enzymatic activity assay or RNase L protein quantification; Gene expression profiling; Evaluation of mitochondrial disorders; Evaluation of enteric dysbiosis.

    12/30/25: removed specialist requirement, updated list of conservative therapies, removed requirement concerning total knee replacement, removed requirement concerning chart notes being required, and clarified requirements in criterion #4d regarding intra-articular steroid injection timing and limits.

    2/4/25: added SynoJoynt as an eligible viscosupplementation treatment option when criteria are met.

    2/8/24: added new coverage criterion requiring failure of one preferred viscosupplement (Synvisc, Synvisc-One, or Euflexxa); noted that these preferred agents do not require prior authorization when administered for osteoarthritis of the knee.

    10/12/23: removed previous criterion that required only certain providers administer this treatment.

    02/03/26Last reviewed
    J7999HCPCS for compounded drugs
    4Exclusions added (2/21/23)
    up to 4 weeksMax IV antibiotic course
    knee onlyJoint(s) covered
    Synvisc/Synvisc‑One/EuflexxaPreferred agents (no PA)

    Coverage Criteria

    Medically Necessary Compounded Prescriptions

    A compounded prescription is considered medically necessary when ALL of the following are met:

    Medically necessary compound criteria: (1) The active ingredient in the compounded product contains at least one legend medication component. (2) The legend medication is FDA approved for medical use in the United States. (3) The active medication component is in therapeutic amounts, based on scientific literature or national compendia. (4) The safety and effectiveness for the compounded medication and its route of administration (including the delivery system) is supported by scientific literature or national compendia.

    All conditions must be met for medical necessity.

    Prescriber justification for variants: If the compound is similar to a commercially available product but differs in dosage, dosage form, or omission of dye/sweetener/flavoring/preservative, clinical documentation from the prescriber supporting the clinical need for the compound is required.

    Documentation must justify why commercially available product is unsuitable.

    Covered diagnostic tests

    Covered diagnostic tests for evaluation of suspected CFS when clinically indicated

    Covered Tests: Antinuclear antibodies (ANA); blood and serum chemistries (serum electrolytes, BUN, glucose, calcium, magnesium, creatinine); complete blood count (CBC) with differential; C-reactive protein (CRP); erythrocyte sedimentation rate (ESR); estradiol/testosterone; FSH; HIV serology; immunoglobulin levels (when recurrent bacterial infections documented); iron levels; liver function tests (LFTs); Lyme serology; MRI of the head (to rule out multiple sclerosis when clinically indicated); polysomnography (to rule out sleep apnea when indicated); rheumatoid factor (RF); serum cortisol; serum protein electrophoresis; thyroid function tests (TSH, free T4, T3); tuberculosis skin test; urinalysis; urine drug screen; vitamin B12.

    Not medically necessary / investigational

    Tests considered investigational and not covered for evaluation of CFS

    Not covered tests: ELISA/ACT testing; evaluation of enteric dysbiosis; evaluation of mitochondrial disorders; functional elevation of natural killer (NK) cells; gene expression profiling; measurements of delayed hypersensitivity; MRI scans except when there is clinical suspicion for MS; production and response to cytokines; quantification of B and T cell subsets; quantification of NK cells; radionuclide scans such as SPECT and PET; RNase L enzymatic activity assay or RNase L protein quantification; serologic tests for Candida albicans; T cell response to mitogenic stimulation; viral serologies (e.g., Coxsackie, Epstein-Barr virus, cytomegalovirus, human herpesvirus-6, enterovirus, retroviruses except HIV).

    Estradiol pellets (Commercial plan)

    Commercial plan stance on estradiol pellet therapy

    Estradiol pellet noncoverage: Select Health does NOT cover implantation of estradiol pellets for treatment of menopausal symptoms or other hormonal deficiencies; this therapy is considered experimental/investigational due to lack of FDA-approved formulations, unpredictable and fluctuating serum concentrations, and safety/reversibility concerns.

    Commercial plan policy: not covered.

    Lyme disease — IV antibiotic use

    Lyme disease antibiotic coverage stance

    Antibiotic duration: Oral antibiotics are usually adequate for Lyme disease; a 2–4 week course of IV antibiotics may be appropriate for Lyme arthritis, carditis, or objective neurologic complications. Evidence has not shown benefit to prolonged (>4 weeks) or repeat courses of IV antibiotics; therefore repeat or prolonged IV antibiotic courses are considered not medically necessary.>4 weeks

    Repeat or prolonged IV antibiotic therapy considered not medically necessary.

    Medically necessary IV antibiotic therapy (up to 4 weeks)

    Covered when ALL of the following are met:

    Core requirements: 1) Laboratory-confirmed Lyme disease with diagnosis established by a board-certified infectious disease specialist; AND 2) A course of intravenous (IV) antibiotics up to 4 weeks; AND 3) The antibiotic is ceftriaxone, cefotaxime, or penicillin G (azithromycin may be used for beta-lactam allergy or intolerance).up to 4 weeks

    All three core requirements must be satisfied.

    Qualifying clinical manifestations: At least ONE of the following: a) myocarditis associated with second- or third-degree AV block, or first-degree heart block with PR interval ≥ 300 ms; b) persistent or recurrent joint swelling (arthritis) after an initial 1-month trial of oral antibiotics; c) acute or chronic neurologic disease affecting the central or peripheral nervous system, including meningitis, any neurologic syndrome with CSF pleocytosis, severe peripheral neurologic syndromes or those following oral therapy failure, encephalomyelitis, or encephalopathy.

    One qualifying manifestation required in addition to core requirements.

    Initial Therapy

    Covered when ALL of the following are met

    Eligibility: Patient is between the ages of 40 and 65 years (exceptions may be considered case-by-case).age 40-65

    Patients outside this range considered case-by-case if otherwise eligible.

    Radiographic confirmation: Documented primary osteoarthrosis (osteoarthritis) of the knee confirmed radiographically with radiologic grade II or III (moderate disease).radiologic grade II or III

    Not eligible for grade I or IV.

    Functional impairment: Moderate to severe functional impairment of the knee due to osteoarthritis as defined in the policy.moderate-severe impairment

    Functional impairment must be documented.

    Continuation and Quantity Limits

    Limits and continuation rules

    Reauthorization interval: Subsequent injections must be reauthorized every 6 months.6 months

    Applies to repeat courses.

    Quantity limits: Product-specific number of injections and course durations must conform to the policy (examples: Euflexxa 3 injections over 3 weeks; Durolane 1 injection; Hyalgan 5 injections over 5 weeks; Orthovisc 4 injections over 4 weeks; Synvisc 3 injections over 3 weeks; Synvisc-One 1 injection).varies by product

    Full list of product limits provided in the policy.

    Initial therapy (medical necessity)

    Covered when ALL of the following are met

    Initial coverage criteria: 1) Patient has symptomatic osteoarthritis (commonly knee OA) with significant pain and/or functional limitation; 2) Conservative therapy has failed (including physical therapy, exercise, and analgesics); 3) Intra-articular corticosteroid injection has been ineffective or is contraindicated; 4) Product dosing and per-course injection limits conform to per-product schedules in the policy.

    Evidence (systematic reviews and RCTs) supports modest symptomatic benefit for HA in responders.

    Continuation/repeat therapy

    Covered when ALL of the following are met

    Repeat treatment: 1) Patient previously responded to an initial course of viscosupplementation with symptomatic improvement; 2) Interval since prior course is consistent with product-specific duration of efficacy (many products up to 6 months for responders); 3) No contraindication such as history of significant local inflammatory reaction to the same product (noted risk with some cross-linked high-MW products such as Synvisc).

    Routine repeat treatments without documented prior response or outside per-product recommended intervals are not supported.

    Updated Commercial Plan Coverage Criteria (summary)

    Commercial Plan coverage updated over time; select material changes include:

    Commercial Plan updated criteria (summary): Failure of one preferred viscosupplement (Synvisc, Synvisc-One, or Euflexxa) is now required before coverage of other viscosupplements; SynoJoynt was added as an eligible option when criteria are met; preferred agents (Synvisc, Synvisc-One, Euflexxa) do not require prior authorization when administered for osteoarthritis of the knee; specialist-only administration and the total knee replacement requirement were removed; intra-articular steroid injection timing/limits clarified (at least 1-month trial within past 6 months; limit of 2 injections).

    These are material revisions recorded in the policy revision history.

    Select Health does NOT cover compounded bio-identical hormone replacement therapy (BHRT). The policy states that compounded BHRT safety and efficacy have not been documented in clinical studies and that BHRT prescriptions are uniquely formulated; therefore coverage for these compounds is not provided under the Commercial Plan criteria.

    As noted in the policy, compounded prescriptions are only covered when they meet all specified requirements (e.g., include at least one FDA-approved legend medication, contain therapeutic amounts, and have safety/effectiveness supported by literature); BHRT products do not meet these criteria and are explicitly excluded.

    Drug compounding that is performed solely for convenience or nonmedical reasons is considered not medically necessary. The policy explains that compounding may be appropriate when a commercially available product does not meet a patient’s clinical needs (for example, unavailable strength, dosage form, or excipient allergy), but routine convenience-based compounding is not covered.

    When a compound is similar to a commercially available product but differs only in dosage, form, or absence of nontherapeutic ingredients (e.g., dye, sweetener, preservative), the prescriber must provide clinical documentation justifying the medical need for the compound; absent such justification, coverage may be denied.

    Select Health does not cover diagnostic tests for evaluation of chronic fatigue syndrome (CFS) that the policy lists as investigational. Examples include ELISA/ACT testing, evaluation of enteric dysbiosis, evaluation of mitochondrial disorders, functional elevation of NK cells, gene expression profiling, radionuclide scans (SPECT, PET), RNase L assays, serologic tests for Candida, viral serologies (except HIV), and several other specialized immune or molecular tests.

    Requests for these listed investigational tests submitted for routine evaluation of CFS will be denied because the policy considers them to lack sufficient evidence of diagnostic utility for confirming or excluding CFS.

    Revision history documents that on 2/21/23 the Commercial Plan Policy explicitly added four diagnostic tests to the list of exclusions for CFS: RNase L enzymatic activity assay or RNase L protein quantification; gene expression profiling; evaluation of mitochondrial disorders; and evaluation of enteric dysbiosis.

    Use of these newly listed tests as part of routine evaluation for CFS may therefore trigger denial under the Commercial Plan policy effective from that revision.

    Select Health limits acceptable intravenous (IV) antibiotic agents for Lyme disease coverage to specified drugs: ceftriaxone, cefotaxime, or penicillin G, with azithromycin as an option for patients with beta-lactam allergy. Use of other IV agents (for example carbapenems, first‑generation cephalosporins, fluoroquinolones, or fluconazole) is considered investigational and is not covered.

    The policy also clarifies that IV antibiotic therapy is appropriate only in defined clinical situations (e.g., Lyme arthritis, carditis, objective neurologic complications) and that use of nonlisted IV agents or indications outside the coverage criteria will not be authorized.

    Home healthcare services related to the administration of IV therapy that is not covered (for example nursing visits to administer noncovered antibiotics, maintenance of central venous catheters, or home care supplies) are themselves not covered. If the IV antibiotic therapy is not authorized, associated home infusion services and supplies will also be denied.

    Viscosupplementation is covered only for the knee. The policy states that viscosupplementation for any joint other than the knee (including TMJ, shoulder, elbow, wrist, hip, and ankle) is considered investigational/experimental and therefore not covered.

    Knee viscosupplementation coverage requires meeting the policy’s knee-specific eligibility and diagnostic criteria and does not extend to other joints.

    Available comparative evidence does not establish clear superiority of high‑molecular‑weight (HMW) versus low‑molecular‑weight (LMW) hyaluronan products. Systematic reviews and meta-analyses report a modest overall benefit of HA injections versus placebo, but heterogeneity among studies limits definitive conclusions about class-wide superiority.

    Individual randomized trials have produced mixed results, and the policy summarizes that relative effectiveness within the HA class cannot be conclusively determined; product selection should therefore follow the policy’s per-product evidence, dosing limits, and documented clinical response rather than an assumption of HMW superiority.

    The revision history records multiple material changes over time, including removal of some prior requirements and exclusions (for example, removal of the specialist-only administration requirement and of certain prior chart-note requirements) and addition of new requirements such as failure of a preferred viscosupplement prior to coverage of non‑preferred agents.

    These changes indicate that certain previous exclusionary or administrative requirements have been eliminated from the current Commercial Plan criteria; providers should consult the current policy text and revision log for details when preparing authorization requests.

    Reiterating policy intent, compounding for convenience is explicitly described as not medically necessary. The policy distinguishes clinically justified compounding (e.g., lack of commercially available strength, excipient allergy) from convenience compounding and will deny coverage for the latter.

    When convenience-driven compounding is proposed, documentation demonstrating a medical need is required to support any coverage consideration; absent such documentation, claims are subject to denial.

    The policy states that the investigational diagnostic tests listed do not confirm or exclude chronic fatigue syndrome (CFS) and are considered not medically necessary for routine evaluation. The IOM-referenced diagnostic threshold guidance is also cited elsewhere in the policy to support use of only clinically indicated, evidence-based testing.

    Because these investigational tests lack validated diagnostic utility for CFS, their use for routine evaluation should not be expected to be covered under the policy.

    Implantable estradiol pellets (compounded subcutaneous 17 beta‑estradiol pellets) are considered experimental/investigational and are not covered for commercial members. The policy cites the absence of FDA‑approved formulations, unpredictable serum release rates, concerns about reversibility and dosing, and safety risks such as bleeding and infection as reasons for noncoverage.

    Given these unresolved safety and pharmacokinetic concerns, implantation of estradiol pellets for menopausal or hormonal indications is excluded from coverage.

    For Lyme disease, the policy considers repeat or prolonged IV antibiotic therapy beyond 4 weeks to be not medically necessary. Systematic evidence and randomized trials have not shown benefit for extended antibiotic courses and have demonstrated increased risk of harm, which informs the policy’s limitation on IV antibiotic duration.

    Thus, requests for extended (>4 weeks) or repeated IV antibiotic courses for Lyme disease will generally be denied unless they meet the limited, policy-defined exceptions.

    The policy enumerates an expanded list of Lyme disease clinical scenarios considered not medically necessary, including prophylactic treatment after a tick bite without clinical findings, treatment of chronic fatigue/fibromyalgia attributed to Lyme, initial treatment of Lyme arthritis without neurologic symptoms, antibiotic-refractory Lyme arthritis after specified prior courses, use of intramuscular antibiotics for Lyme disease, and use of non‑recommended IV agents or investigational tests to justify continued IV therapy.

    Providers must document laboratory-confirmed Lyme disease and qualifying clinical manifestations per the policy to support authorization; many other clinical scenarios are excluded from coverage.

    The policy requires radiographic confirmation of knee osteoarthritis with radiologic grade II or III (moderate disease) for eligibility; patients with grade I (mild) or grade IV (severe) disease are listed as not eligible for viscosupplementation coverage.

    Functional impairment must also be at least moderate. These radiographic and functional thresholds are enforced when evaluating coverage requests for knee viscosupplementation.

    Routine repeat viscosupplementation without prior documented response or outside the per-product recommended course/dosing is not supported. The policy requires documentation of prior symptomatic improvement following an initial course and adherence to per-product injection counts and interval recommendations for repeat treatments.

    The revision history further clarifies operational updates (for example, preferred-agent sequencing and product additions), but the core requirement remains that repeat treatments be justified by prior documented benefit and conform to product-specific schedules.

    The revision history shows that some prior explicit 'not medically necessary' statements or administrative requirements were removed or revised across updates (for example, removal of the specialist-only administration requirement and elimination of a chart‑notes requirement). The chunks provided here do not contain every previous NMN statement; therefore, absence of a specific NMN phrase in these chunks does not imply that a given scenario is covered.

    Providers should consult the full, current policy and revision log for precise current NMN language and for operational details that affect authorization decisions.

    Coding

    CPT CodesCPT
    No specific CPT codes identified
    HCPCS CodesHCPCS
    J7999Compounded drug, not otherwise classified
    Enumerated procedure and lab codesmixed
    70551Magnetic resonance imaging, brain; without contrast material
    70552Magnetic resonance imaging, brain; with contrast material(s)
    70553Magnetic resonance imaging, brain; without contrast, followed by contrast and further sequences
    80048Basic metabolic panel (calcium, total)
    80050General health panel
    80051Electrolytes panel
    81000Urinalysis, dip stick or tablet reagent; non-automated, with microscopy
    81001Urinalysis, automated with microscopy
    81002Urinalysis, non-automated, without microscopy
    81003Urinalysis, automated, without microscopy
    1–10 of 41
    1/5
    CPT codes for estradiol pellet proceduresCPT
    11980Subcutaneous hormone pellet implantation (implantation of estradiol and/or testosterone pellets beneath the skin)
    11982Removal, non-biodegradable drug delivery implant
    11983Removal with reinsertion, non-biodegradable drug delivery implant
    CPT CODESCPT
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour
    96366Each additional hour
    96367Additional sequential infusion of a new drug/substance, up to 1 hour
    96368Concurrent infusion
    96372Therapeutic, prophylactic or diagnostic injection; subcutaneous or intramuscular
    HCPCS CODES (from document section including various J- and S- codes)HCPCS
    J0456Injection, azithromycin, 500 mg
    J0696Injection, ceftriaxone sodium, per 250 mg
    J0698Injection, cefotaxime sodium, per gm
    J2540Injection, penicillin G potassium, up to 600,000 units [IV]
    S9494Home infusion therapy, antibiotic, antiviral, or antifungal therapy; per diem
    S9497Home infusion therapy; once every 3 hours; per diem
    S9500Home infusion therapy; once every 24 hours
    S9501Home infusion therapy; once every 12 hours
    S9502Home infusion therapy; once every 8 hours
    S9503Home infusion therapy; once every 6 hours
    1–10 of 22
    1/3
    CPT Codes (covered)CPTCovered
    20610Arthrocentesis, aspiration and/or injection, major joint or bursa; without ultrasound guidance
    20611Arthrocentesis, aspiration and/or injection, major joint or bursa; with ultrasound guidance, with permanent recording and reporting
    HCPCS Codes (covered)HCPCSCovered
    J3490Unclassified drug
    J7318Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
    J7320Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg
    J7321Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose
    J7322Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg
    J7323Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
    J7324Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
    J7325Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg
    J7326Hyaluronan or derivative, gel-one, for intra-articular injection, per dose
    J7327Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose
    1–10 of 14
    1/2
    Symptom frequency/severity — diagnostic threshold (IOM)
    IOM diagnostic thresholdCore CFS symptoms present at least half of the time with moderate, substantial, or severe intensity
    Duration contextCFS considered subset of chronic fatigue: unexplained fatigue ≥6 months (supports threshold application)
    Clinical evaluation requiredDiagnosis requires thorough history and physical plus mental status exam to identify psychiatric/neurologic contributors
    Per-course injection counts — examples (product-specific)
    Euflexxa

    Provider Actions & Requirements

    Note

    Medicare & Program-Specific Coverage

    Medicare and other program-specific coverage determinations take precedence where applicable. For Medicare members, follow CMS/NCD/LCD decisions; if CMS has not adopted a determination and InterQual criteria are unavailable, the SelectHealth Commercial policy applies. For Select Health Community Care (Medicaid), policies typically align with Utah Medicaid (including InterQual); NCD/LCD or SelectHealth Commercial criteria may be used in some situations.

    • Medicare: follow CMS coverage determinations first; if absent and InterQual unavailable, apply SelectHealth Commercial policy.
    • Community Care (Medicaid): align with State of Utah Medicaid and InterQual; may defer to NCD/LCD or SelectHealth Commercial when applicable.
    Prior Authorization

    Prior Authorization Requirements

    Prior authorization (PA) is required for certain products and services and coverage is limited to the criteria listed in the applicable policy. Preferred viscosupplement agents (Synvisc, Synvisc‑One, Euflexxa) do not require prior authorization when administered for osteoarthritis of the knee. Non-preferred or variant commercial products and many IV antibiotic courses require PA and supporting documentation.

    Background

    Drug compounding is defined in the policy as the preparation, mixing, or alteration of medications by a pharmacist or physician to meet an individual patient’s needs; it may be appropriate when commercial products are unavailable in required strengths or forms or when patients have allergies to excipients.

    However, the policy emphasizes that compounding must address a documented medical need to be considered for coverage; routine compounding for convenience is explicitly not covered.

    Definitions

    BHRT definition and coverage note
    DefinitionBio-identical hormone therapy (BHRT) defined as supplementation of hormones biochemically similar or identical to endogenous hormones
    Safety/evidence noteSafety and efficacy of compounded BHRT have not been documented in clinical studies
    Coverage stanceCompounded BHRT (implantable or compounded) is not covered / considered experimental/investigational
    Diagnostic threshold — IOM diagnostic threshold for CFS symptom frequency/severity
    IOM diagnostic criterionDiagnosis should be questioned if core ME/CFS symptoms are not present at least half of the time with moderate, substantial, or severe intensity
    ApplicationUse symptom frequency/severity threshold when documenting suspected CFS in clinical records

    Initial Therapy Criteria

    Guideline-based initial therapy

    Preferred initial therapy and durations per clinical guidelines

    Guideline recommendations: Oral antibiotics are recommended for early Lyme disease without neurologic or cardiac involvement (typically 14–21 days). IV ceftriaxone, cefotaxime, or penicillin G are recommended for CNS manifestations or significant neurologic disease, generally for 14–28 days.

    Select Health aligns coverage with guideline indications for IV use.

    Initial Therapy Requirements

    Initial coverage requirements

    Age: Patient between 40 and 65 years unless exception considered case-by-case.
    Radiographic confirmation: Primary knee osteoarthritis confirmed radiographically with radiologic grade II or III.

    Continuation Criteria

    Continuation Therapy

    Reauthorization and product-specific courses

    Reauthorization: Subsequent injections require reauthorization every 6 months.
    Product-specific courses: Per-product number of injections and course durations must be followed (see policy quantity limits list).

    Continuation therapy

    Repeat treatment permitted when prior response documented and timing consistent with product evidence

    Repeat HA therapy: Documented prior clinical response to an initial course; interval since prior course consistent with product-specific duration of efficacy (commonly up to 6 months for responders); and absence of significant prior adverse local inflammatory reaction to the same product.

    Step Therapy

    StepRequirementNotes
    1IV therapy may be authorized when oral therapy has failed or is not tolerated and qualifying clinical criteria are metQualifying manifestations include myocarditis with advanced AV block; persistent/recurrent arthritis after a 1-month trial of oral antibiotics; or acute/chronic CNS or PNS neurologic disease (e.g., meningitis, CSF pleocytosis, severe peripheral neuropathy). Documentation must include laboratory-confirmed Lyme disease and specialist diagnosis.
    StepRequirementNotes
    1Trial of a preferred viscosupplement required before coverage of other productsPreferred agents are Synvisc, Synvisc-One, and Euflexxa; these preferred agents do not require prior authorization for osteoarthritis of the knee.
    PlanRequirementNotes
    Commercial PlanMust try and fail one preferred agent (Synvisc, Synvisc-One, or Euflexxa) before coverage of other viscosupplementsRequirement added in 2/8/24 revision; preferred agents are exempt from prior authorization for knee OA. Documentation of failure should follow policy conservative-therapy and product-specific criteria.

    Quantity Limits

    Euflexxa per-course injection count
    Euflexxa per-course count3 injections per treatment course (3‑week course)
    Course duration3 weeks
    Source notePer‑product quantity limits listed in policy quantity table
    Durolane per-course injection count
    Durolane per-course count1 injection per treatment course (single administration)
    Course durationSingle administration
    Source notePer‑product quantity limits listed in policy quantity table

    Site of Care

    Billing Rule

    Home health services for noncovered IV therapy are not covered

    Home health services (nursing visits, catheter maintenance, supplies) for administration of IV therapy that is not covered are not covered and may be denied.

    • Select Health does not cover home healthcare services related to noncovered IV antibiotic therapy.

    Revision History

    2025-12-30revisedLatest

    Removed specialist requirement; updated conservative therapies list; removed total knee replacement requirement; removed chart notes requirement; clarified intra-articular steroid injection timing and limits (at least 1-month trial within past 6 months; limit of 2 injections).

    2023-02-21added

    For the Commercial Plan, added four diagnostic tests to the exclusions list for evaluation of chronic fatigue syndrome: RNase L enzymatic activity assay or RNase L protein quantification; gene expression profiling; evaluation of mitochondrial disorders; and evaluation of enteric dysbiosis.

    Policy Summary
    PayerSelectHealth
    PolicyCompounded Medications
    Policy CodePolicy 325
    Change TypeMaterial revisions and multiple prior updates (additions and clarifications)
    Effective DateDec 21, 2023
    Last ReviewFeb 3, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and provide clinical documentation showing the compound contains at least one FDA‑approved legend drug in therapeutic amounts and justification if similar to a commercial product.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & RequirementsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep TherapyQuantity LimitsSite of CareRevision History
    Conservative therapy failure: Failed conservative therapies or therapies are not tolerated/contraindicated: weight reduction/activity modification, physical therapy, prescription-strength NSAIDs (≥1-month trial within past 6 months), and intra-articular steroid injection (≥1-month trial within past 6 months; limit of 2 injections).specified trials

    All listed conservative therapies must have been tried unless contraindicated.

    Preferred agent trial: Failure of one preferred viscosupplement (Synvisc, Synvisc-One, or Euflexxa) is required prior to coverage of other products. Preferred agents do not require prior authorization for knee OA.trial of preferred agent

    Documentation of failure required for non-preferred agents.

    Product approval: Viscosupplementation product must be FDA approved and used according to per-product dosing/schedule.FDA approval

    Per-product quantity limits and course schedules apply.

    3 injections per treatment course (3-week course)
    Durolane1 injection per treatment course (single administration)
    Hyalgan5 injections per treatment course (5-week course)
    • Preferred viscosupplements (Synvisc, Synvisc‑One, Euflexxa): no PA required for knee OA when criteria met.
    • Non-preferred hyaluronan products and J3490 billed hyaluronans: PA required; submit clinical documentation per product-specific schedules and quantity limits.
    • IV antibiotics for Lyme disease: PA required; coverage limited to specified clinical criteria and duration (typically ≤4 weeks).
    Documentation Required

    Prescriber Clinical Justification & Step Requirements

    Prescribers must provide clinical justification when requesting compounded medications that differ from available commercial products (differences in dosage, dosage form, or omission of excipients). For variant commercial products or non‑preferred agents, the prescriber should document why the preferred agent is not appropriate or has failed.

    • Clinical justification required when a compound or commercial variant differs from an FDA‑approved product (dose, form, excipient changes).
    • For viscosupplementation beyond preferred agents, document failure of one preferred agent (Commercial plan) before approving non‑preferred products.
    Denial Risk

    Investigational / Excluded Diagnostic Tests — Denial Risk

    Be aware of specific investigational or excluded diagnostic tests and that use of these tests may trigger claim denials. Requests for tests listed as investigational/denied should be expected to be denied unless compelling, documented rationale is provided and falls within limited exceptions.

    • Denied/excluded diagnostic tests for CFS include: RNAse L enzymatic activity assay or RNase L protein quantification; Gene expression profiling; Evaluation of mitochondrial disorders; Evaluation of enteric dysbiosis; and others listed in the CFS diagnostic testing policy.
    • Use of excluded Lyme tests (e.g., PCR-based urine detection, genotyping/phenotyping, C6 peptide ELISA, CXCL13, direct probe/quantification techniques) is considered experimental/investigational and may be denied.
    Documentation Required

    Documentation & Benefit Applicability

    Document the clinical indication and relevant benefit information with all PA requests. Provide symptom history, prior treatments tried and outcomes, and applicable member benefit details. For Lyme disease IV therapy, include laboratory confirmation and involvement/diagnosis by a board‑certified infectious disease specialist when required.

    • Include clinical indication, duration of symptoms, prior conservative therapies and responses, and member benefit/plan info with requests.
    • Lyme IV antibiotics: provide lab-confirmed diagnosis and documentation that a board‑certified infectious disease specialist established the diagnosis when required.
    • Viscosupplementation: include radiographic confirmation and radiologic grade II/III documentation and evidence of failure of conservative therapies; follow per-product quantity/course limits.
    Billing Rule

    Quantity, Course Limits & Documentation Expectations

    Follow published product quantity and course limits and reauthorization requirements. Failure to document required prior steps or preferred‑agent failure may lead to denial. Chart note requirements were removed in later revisions, but adhere to current criteria and documentation expectations.

    • Adhere to per-product injection counts and course schedules (e.g., Euflexxa = 3 injections/course; Synvisc = 3 injections; Durolane = 1 injection).
    • Subsequent viscosupplementation injections require reauthorization every 6 months.
    • Not documenting failure of required conservative therapy or of one preferred viscosupplement (Commercial) is a common denial trigger.
    Note

    Coverage, Contact & Provider Actions

    For questions about member benefits or policy interpretation, contact SelectHealth Provider Relations or Member Customer Service. Always verify member eligibility and specific benefit coverage prior to submitting authorization requests.

    • Members: call the phone number on the member ID card for benefit questions.
    • Providers: contact SelectHealth Provider Relations at (801) 442‑3692 for policy or PA questions.
    • Verify member-specific benefit coverage and plan type (Commercial, Medicare, Community Care) before proceeding.
    Step Therapy

    Step Therapy & Placement After Conservative Treatment

    Step‑therapy placement: viscosupplementation is considered after failure of conservative therapies (weight loss/activity modification, physical therapy, prescription NSAIDs, and intra‑articular steroid—limit 2 injections). For Lyme disease, oral therapy is preferred; IV therapy is reserved for specified cardiac, neurologic, or oral‑therapy‑failure situations.

    • Viscosupplementation considered only after documented failure/intolerance of listed conservative measures.
    • Lyme disease: reserve IV antibiotics for myocarditis with conduction block, persistent/recurrent arthritis after oral therapy, or neurologic involvement, or when oral therapy fails or is not tolerated.
    Supporting evaluationPerform thorough history, physical, and mental status exam to identify other psychiatric, neurologic, or cognitive disorders
    Estradiol pellets — definition and description
    DefinitionEstradiol pellets are pharmacy‑compounded hard crystals of 17β‑estradiol intended for subcutaneous implantation
    PharmacokineticsEach pellet releases estradiol over ~3–4 months, proposed steady therapeutic levels (~150–250 pg/mL)
    Coverage stanceImplantable estradiol pellets are considered experimental/investigational and not covered due to safety and release‑rate concerns
    Lyme disease — definition
    DefinitionLyme disease is a multisystem inflammatory disease caused by Borrelia burgdorferi transmitted by ixodid ticks
    Typical managementOral antibiotics usually adequate; IV antibiotics reserved for specific manifestations (e.g., arthritis, carditis, neurologic complications)
    Coverage implicationRepeat or prolonged (>4 weeks) IV antibiotic courses are considered not medically necessary
    Laboratory-confirmed Lyme disease — diagnostic confirmation definition
    Laboratory confirmationDiagnosis must be laboratory‑confirmed and established by a board‑certified infectious disease specialist
    Qualifying manifestationsQualifying indications include myocarditis with advanced AV block, persistent/recurrent arthritis after 1 month oral antibiotics, or CNS/PNS neurologic disease as specified
    Course limitWhen indicated, IV antibiotic therapy is limited to a course of up to 4 weeks
    Viscosupplementation — definition of intra-articular hyaluronan therapy
    DefinitionViscosupplementation is intra‑articular injection of sodium hyaluronate (hyaluronan) or Hylan G‑F 20 to restore synovial fluid lubrication and improve joint function/pain
    MechanismHA restores viscoelastic properties of synovial fluid and may have analgesic and anti‑inflammatory effects
    Approved productsMultiple FDA‑approved HA products exist for knee OA (see product list in policy)
    High‑MW vs Low‑MW HA — definition and differences
    DefinitionHigh‑MW versus low‑MW HA products differ by molecular weight, concentration, treatment schedule, and production method
    EvidenceSystematic reviews show modest benefit for HA overall but inconsistent evidence that high‑MW products are clinically superior to low‑MW products
    Clinical implicationProduct selection should follow per‑product evidence and policy quantity/course limits rather than presumed MW superiority
    Conservative therapy — definition (noninvasive treatments list)
    DefinitionConservative therapy = noninvasive treatments such as physical therapy, exercise, weight/activity modification, occlusal alignment/bite plates (for TMJ), nonprescription analgesics, and trial of intra‑articular corticosteroids
    Steroid trial requirementPolicy specifies intra‑articular corticosteroid trial ≥1 month within past 6 months (limit of 2 injections) as part of conservative therapy for viscosupplementation eligibility
    PurposeViscosupplementation is considered after failure of these conservative measures or when they are contraindicated/intolerable
    Hylan G‑F 20 / Hyaluronan / Sodium hyaluronate — examples of products
    ExamplesHylan G‑F 20 (Synvisc), Hyalgan, Orthovisc, ARTZ, Euflexxa, Durolane, Gel‑One, Gelsyn‑3, Monovisc, Hymovis, Synvisc‑One, Supartz Fx, TriVisc, Triluron, GenVisc, SynoJoynt, VISCO‑3
    Product classThese are injectable hyaluronan/hyaluronate derivatives used intra‑articularly for knee OA
    Coding noteMany of these products have specific HCPCS codes listed in the policy (J7320–J7332, J7318, plus J3490 for unclassified drug)
    Conservative therapy failure: Required trials include weight reduction/activity modification, physical therapy, prescription NSAID trial of at least 1 month within past 6 months, and intra-articular steroid injection trial of at least 1 month within past 6 months (limit of 2 injections).

    Initial Therapy

    Initial course coverage

    Initial HA therapy: Symptomatic knee osteoarthritis with significant pain/functional limitation; failure of conservative therapy; intra-articular corticosteroids ineffective or contraindicated; and use of product-specific dosing/course as listed in the policy.

    Evidence reviews report modest benefit for HA versus placebo; single-course treatment supported when prior therapies failed.

    Preferred-agent initial therapy

    Preferred-agent sequencing and authorization notes from revision history.

    Preferred agent use: Synvisc, Synvisc-One, or Euflexxa are preferred viscosupplements and do not require prior authorization when used for osteoarthritis of the knee. Coverage of other agents requires documented failure of one preferred agent per the updated Commercial Plan criteria.

    Derived from the 2/8/24 and 2/4/25 revision history entries.

    Evidence for repeat treatment safety/effectiveness is limited; Synvisc may have higher local inflammatory reactions.

    Gel-One per-course injection count
    Gel‑One per-course count1 injection per treatment course (single administration)
    Course durationSingle administration
    Source notePer‑product quantity limits listed in policy quantity table
    Gelsyn-3 per-course injection count
    Gelsyn‑3 per-course count3 injections per treatment course (3‑week course)
    Course duration3 weeks
    Source notePer‑product quantity limits listed in policy quantity table
    Hyalgan per-course injection count
    Hyalgan per-course count5 injections per treatment course (5‑week course)
    Course duration5 weeks
    Source notePer‑product quantity limits listed in policy quantity table
    Hymovis per-course injection count
    Hymovis per-course count1 injection per treatment course (single administration)
    Course durationSingle administration
    Source notePer‑product quantity limits listed in policy quantity table
    Monovisc per-course injection count
    Monovisc per-course count1 injection per treatment course (single administration)
    Course durationSingle administration
    Source notePer‑product quantity limits listed in policy quantity table
    Orthovisc per-course injection count
    Orthovisc per-course count4 injections per treatment course (4‑week course)
    Course duration4 weeks
    Source notePer‑product quantity limits listed in policy quantity table
    SynoJoynt per-course injection count
    SynoJoynt per-course count3 injections per treatment course (3‑week course)
    Course duration3 weeks
    Source noteSynoJoynt added as eligible agent per revision history; per‑product limits apply
    Synvisc-One per-course injection count
    Synvisc‑One per-course count1 injection per treatment course (single administration)
    Course durationSingle administration
    Source notePer‑product quantity limits listed in policy quantity table
    Synvisc per-course injection count
    Synvisc per-course count3 injections per treatment course (3‑week course)
    Course duration3 weeks
    Safety noteRepeat Synvisc courses may have increased local inflammatory reactions per literature
    Supartz Fx per-course injection count
    Supartz Fx per-course count5 injections per treatment course (5‑week course)
    Course duration5 weeks
    Source notePer‑product quantity limits listed in policy quantity table
    TriVisc per-course injection count
    TriVisc per-course count3 injections per treatment course (3‑week course)
    Course duration3 weeks
    Source notePer‑product quantity limits listed in policy quantity table
    Triluron per-course injection count
    Triluron per-course count3 injections per treatment course (3‑week course)
    Course duration3 weeks
    Source notePer‑product quantity limits listed in policy quantity table
    GenVisc per-course injection count
    GenVisc per-course count5 injections per treatment course (5‑week course)
    Course duration5 weeks
    Source notePer‑product quantity limits listed in policy quantity table
    VISCO-3 per-course injection count
    VISCO‑3 per-course count3 injections per treatment course (3‑week course)
    Course duration3 weeks
    Source notePer‑product quantity limits listed in policy quantity table
    Euflexxa (duplicate) per-course injection count
    Euflexxa per-course count (duplicate)3 injections per treatment course (3‑week course)
    NoteDuplicate entry mirrors primary Euflexxa listing
    SourcePolicy quantity limits table
    Durolane (duplicate) per-course injection count
    Durolane per-course count (duplicate)1 injection per treatment course (single administration)
    NoteDuplicate entry mirrors primary Durolane listing
    SourcePolicy quantity limits table
    Gel-One (duplicate) per-course injection count
    Gel‑One per-course count (duplicate)1 injection per treatment course (single administration)
    NoteDuplicate entry mirrors primary Gel‑One listing
    SourcePolicy quantity limits table
    Gelsyn-3 (duplicate) per-course injection count
    Gelsyn‑3 per-course count (duplicate)3 injections per treatment course (3‑week course)
    NoteDuplicate entry mirrors primary Gelsyn‑3 listing
    SourcePolicy quantity limits table
    Hyalgan (duplicate) per-course injection count
    Hyalgan per-course count (duplicate)5 injections per treatment course (5‑week course)
    NoteDuplicate entry mirrors primary Hyalgan listing
    SourcePolicy quantity limits table
    Hymovis (duplicate) per-course injection count
    Hymovis per-course count (duplicate)1 injection per treatment course (single administration)
    NoteDuplicate entry mirrors primary Hymovis listing
    SourcePolicy quantity limits table
    Monovisc (duplicate) per-course injection count
    Monovisc per-course count (duplicate)1 injection per treatment course (single administration)
    NoteDuplicate entry mirrors primary Monovisc listing
    SourcePolicy quantity limits table
    Orthovisc (duplicate) per-course injection count
    Orthovisc per-course count (duplicate)4 injections per treatment course (4‑week course)
    NoteDuplicate entry mirrors primary Orthovisc listing
    SourcePolicy quantity limits table
    SynoJoynt (duplicate) per-course injection count
    SynoJoynt per-course count (duplicate)3 injections per treatment course (3‑week course)
    NoteDuplicate entry mirrors primary SynoJoynt listing
    SourcePolicy quantity limits table and revision history
    Synvisc-One (duplicate) per-course injection count
    Synvisc‑One per-course count (duplicate)1 injection per treatment course (single administration)
    NoteDuplicate entry mirrors primary Synvisc‑One listing
    SourcePolicy quantity limits table
    Synvisc (duplicate) per-course injection count
    Synvisc per-course count (duplicate)3 injections per treatment course (3‑week course)
    NoteDuplicate entry mirrors primary Synvisc listing
    Safety noteSee literature noting increased local reactions with repeat Synvisc courses
    Supartz Fx (duplicate) per-course injection count
    Supartz Fx per-course count (duplicate)5 injections per treatment course (5‑week course)
    NoteDuplicate entry mirrors primary Supartz listing
    SourcePolicy quantity limits table
    TriVisc (duplicate) per-course injection count
    TriVisc per-course count (duplicate)3 injections per treatment course (3‑week course)
    NoteDuplicate entry mirrors primary TriVisc listing
    SourcePolicy quantity limits table
    Triluron (duplicate) per-course injection count
    Triluron per-course count (duplicate)3 injections per treatment course (3‑week course)
    NoteDuplicate entry mirrors primary Triluron listing
    SourcePolicy quantity limits table
    GenVisc (duplicate) per-course injection count
    GenVisc per-course count (duplicate)5 injections per treatment course (5‑week course)
    NoteDuplicate entry mirrors primary GenVisc listing
    SourcePolicy quantity limits table
    VISCO-3 (duplicate) per-course injection count
    VISCO‑3 per-course count (duplicate)3 injections per treatment course (3‑week course)
    NoteDuplicate entry mirrors primary VISCO‑3 listing
    SourcePolicy quantity limits table